In this webinar, Dr. Boland and Dr. Polaske will highlight infectious disease and vaccine research, presenting published studies where immunoSEQ Technology was leveraged. Topics will include repertoire properties associated with disease and vaccine responses, identifying antigen-specific clones, tracking clones over time and how repertoire and clone-level data can be integrated with clinical data to drive understanding and progress in the field.
Additionally, the speakers will describe different ways to work with Adaptive Biotechnologies, including an upgraded human T-Cell Receptor Beta (TCRB) Kit to perform the gold-standard immunosequencing in the lab, as well as collaboration opportunities to help build the TCR-Antigen Map.
Katie Boland, DVM, PhD, Senior Manager, Scientific Services
Dr. Katie Boland is a veterinary pathologist and immunologist with 19 years of research experience and is an expert in the field of immunosequencing. Her current role at Adaptive Biotechnologies is leading a team of scientific liaisons and other scientific and technical support experts to help Adaptive’s academic customers incorporate immunosequencing into a broad range of research applications. Dr. Boland holds a PhD in Immunology from Washington State University where she focused on T-cells in mucosal immunity and vaccine development, while concurrently completing a veterinary anatomic pathology residency. She also holds a Doctor of Veterinary Medicine from Michigan State University and a Bachelor of Arts in Biochemistry from Case Western Reserve University.
Nathan Polaske, PhD, Scientific Liaison, Research Products
Dr. Nate Polaske is an organic chemist with 15 years of research and development experience in cancer diagnostics and therapeutics. Dr. Polaske holds a PhD in organic chemistry from the University of Arizona where he focused on the identification, design and synthesis of biologically active small molecules for targeted cancer therapy. More recently, he developed novel detection and amplification chemistries for protein, RNA and protein proximity for application to cancer in-vitro diagnostic assays. In his current role as a scientific liaison for Adaptive Biotechnologies, he works closely with academic customers, providing technical support and training across Adaptive’s research product portfolio.
Who Should Attend?
- Academic and pharma infectious disease and/or vaccine researchers
- Infectious disease specialists
immunoSEQ is for Research Use Only. Not for use in diagnostic procedures.
What You Will Learn
In this webinar, attendees will learn about:
- Adaptive’s immunoSEQ Technology, sequencing T- and B-cell receptors at high throughput and applications in both infectious diseases and vaccine development
- How immunosequencing can be used to understand infectious disease pathology, and relatedly, vaccine development and responses
- How through its TCR-Antigen Map program, Adaptive intends to build better diagnostics for infectious diseases and is actively seeking collaborators
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have two commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.